PAI-1 and atherothrombosis

被引：371

作者：

Vaughan, DE ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37232 USA

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2005年 / 3卷 / 08期

关键词：

fibrinolysis; inhibitor-1; plasminogen activator; risk factors; thrombosis;

D O I：

10.1111/j.1538-7836.2005.01420.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of tissue-type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI-1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI-1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI-1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI-1 excess promotes the development of intravascular thrombosis and atherosclerosis.

引用

页码：1879 / 1883

页数：5

共 81 条

[1] Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity [J].

Alessi, MC ;

Bastelica, D ;

Morange, P ;

Berthet, B ;

Leduc, I ;

Verdier, M ;

Geel, O ;

Juhan-Vague, I .

DIABETES, 2000, 49 (08) :1374-1380

[2] Proteinases and extracellular matrix remodeling [J].

Alexander, C. M. ;

Werb, Z. .

CURRENT OPINION IN CELL BIOLOGY, 1989, 1 (05) :974-982

[3] MAJOR CIRCADIAN FLUCTUATIONS IN FIBRINOLYTIC FACTORS AND POSSIBLE RELEVANCE TO TIME OF ONSET OF MYOCARDIAL-INFARCTION, SUDDEN CARDIAC DEATH AND STROKE [J].

ANDREOTTI, F ;

DAVIES, GJ ;

HACKETT, DR ;

KHAN, MI ;

DEBART, ACW ;

ABER, VR ;

MASERI, A ;

KLUFT, C .

AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (09) :635-637

[4] DIURNAL-VARIATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RAPID INHIBITOR (PAI-1) [J].

ANGLETON, P ;

CHANDLER, WL ;

SCHMER, G .

CIRCULATION, 1989, 79 (01) :101-106

[5] ROLE OF OXIDATIVE STRESS IN DEVELOPMENT OF COMPLICATIONS IN DIABETES [J].

BAYNES, JW .

DIABETES, 1991, 40 (04) :405-412

[6] ATHEROGENESIS IN DIABETES [J].

BIERMAN, EL .

ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (06) :647-656

[7] Platelets synthesize large amounts of active plasminogen activator inhibitor 1 [J].

Brogren, H ;

Karlsson, L ;

Andersson, M ;

Wang, LW ;

Erlinge, D ;

Jern, S .

BLOOD, 2004, 104 (13) :3943-3948

[8] Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 [J].

Brown, NJ ;

Agirbasli, MA ;

Williams, GH ;

Litchfield, WR ;

Vaughan, DE .

HYPERTENSION, 1998, 32 (06) :965-971

[9] Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production [J].

Brown, NJ ;

Kim, KS ;

Chen, YQ ;

Blevins, LS ;

Nadeau, JH ;

Meranze, SG ;

Vaughan, DE .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :336-344

[10] PLASMINOGEN DEFICIENCY CAUSES SEVERE THROMBOSIS BUT IS COMPATIBLE WITH DEVELOPMENT AND REPRODUCTION [J].

BUGGE, TH ;

FLICK, MJ ;

DAUGHERTY, CC ;

DEGEN, JL .

GENES & DEVELOPMENT, 1995, 9 (07) :794-807

← 1 2 3 4 5 6 7 8 9 →